Choksi Laboratories Limited has submitted a regulatory disclosure to BSE Limited regarding the outcome of its proposed preferential issue of convertible warrants.
The company informs that the proposal for issuance of convertible warrants on a preferential basis, which was placed before shareholders at the Extra-Ordinary General Meeting held on Saturday, October 17, 2026, was not approved by the shareholders.
As a result of this non-approval, the company will not proceed with the proposed preferential issue of convertible warrants and shall not take any further steps in relation to this proposal.
Notably, the Promoters and the proposed allottees in the preferential issue abstained from voting on the resolution at the EGM.
In light of these developments, the company has requested BSE Limited to close the application for in-principle approval that was previously submitted in connection with this proposed preferential issue of convertible warrants.
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.